These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 20333868

  • 1. Serum osteoprotegrin (OPG) and receptor activator of nuclear factor kappaB (RANKL) in healthy children and adolescents.
    Wasilewska A, Rybi-Szuminska AA, Zoch-Zwierz W.
    J Pediatr Endocrinol Metab; 2009 Dec; 22(12):1099-104. PubMed ID: 20333868
    [Abstract] [Full Text] [Related]

  • 2. sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.
    Doumouchtsis KK, Kostakis AI, Doumouchtsis SK, Tziamalis MP, Tsigris C, Kostaki MA, Perrea DN.
    J Endocrinol Invest; 2007 Oct; 30(9):762-6. PubMed ID: 17993768
    [Abstract] [Full Text] [Related]

  • 3. LMS-based continuous pediatric reference values for soluble receptor activator of nuclear factor kappa B ligand (sRANKL) and osteoprotegerin (OPG) in the HARP cohort.
    Tietze H, Pott V, Kanzelmeyer N, Memaran N, Baumann U, Mindermann C, Suhlrie A, Drube J, Melk A, Das AM, Schnabel D, Haffner D, Leifheit-Nestler M.
    Osteoporos Int; 2024 Mar; 35(3):533-542. PubMed ID: 37940696
    [Abstract] [Full Text] [Related]

  • 4. RANKL/RANK/OPG system and bone status in females with anorexia nervosa.
    Ostrowska Z, Ziora K, Oświęcimska J, Swiętochowska E, Szapska B, Wołkowska-Pokrywa K, Dyduch A.
    Bone; 2012 Jan; 50(1):156-60. PubMed ID: 22001124
    [Abstract] [Full Text] [Related]

  • 5. Selected pro-inflammatory cytokines, bone metabolism, osteoprotegerin, and receptor activator of nuclear factor-kB ligand in girls with anorexia nervosa.
    Ostrowska Z, Ziora K, Oświęcimska J, Marek B, Świętochowska E, Kajdaniuk D, Strzelczyk J, Cieślicka A, Wołkowska-Pokrywa K, Kos-Kudła B.
    Endokrynol Pol; 2015 Jan; 66(4):313-21. PubMed ID: 26323468
    [Abstract] [Full Text] [Related]

  • 6. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
    Doumouchtsis K, Perrea D, Doumouchtsis S, Tziamalis M, Poulakou M, Vlachos I, Kostakis A.
    Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Circulating osteoprotegerin and soluble RANK ligand in systemic sclerosis.
    Dovio A, Data V, Carignola R, Calzolari G, Vitetta R, Ventura M, Saba L, Severino A, Angeli A.
    J Rheumatol; 2008 Nov; 35(11):2206-13. PubMed ID: 18843778
    [Abstract] [Full Text] [Related]

  • 9. Osteoprotegerin and receptor activator of the nuclear factor kappa B ligand (RANKL) in healthy pubertal girls - relationships with physical growth and classical bone turnover markers.
    Kulik-Rechberger B, Kozłowska M.
    J Physiol Pharmacol; 2024 Feb; 75(1):. PubMed ID: 38583439
    [Abstract] [Full Text] [Related]

  • 10. Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
    Todenhöfer T, Hennenlotter J, Leidenberger P, Wald A, Hohneder A, Kühs U, Mischinger J, Aufderklamm S, Gakis G, Blumenstock G, Stenzl A, Schwentner C.
    BJU Int; 2014 Jan; 113(1):152-9. PubMed ID: 23360112
    [Abstract] [Full Text] [Related]

  • 11.  Dehydroepiandrosterone sulfate, osteoprotegerin and its soluble ligand sRANKL and bone metabolism in girls with anorexia nervosa.
    Ostrowska Z, Ziora K, Oświęcimska J, Swiętochowska E, Wołkowska-Pokrywa K.
    Postepy Hig Med Dosw (Online); 2012 Sep 12; 66():655-62. PubMed ID: 23001207
    [Abstract] [Full Text] [Related]

  • 12. [Concentration measurement of the OPG and sRANKL of peripheral blood among normal healthy people].
    Zhu LL, Bao NR, Zhou LW, Guo T, Zeng XF, Zhao JN.
    Zhongguo Gu Shang; 2010 Feb 12; 23(2):87-9. PubMed ID: 20345025
    [Abstract] [Full Text] [Related]

  • 13. Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients.
    Carmona-Fernandes D, Santos MJ, Perpétuo IP, Fonseca JE, Canhão H.
    Arthritis Res Ther; 2011 Feb 12; 13(5):R175. PubMed ID: 22027240
    [Abstract] [Full Text] [Related]

  • 14. Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?
    Kananen K, Volin L, Laitinen K, Ruutu T, Välimäki MJ.
    Osteoporos Int; 2006 Feb 12; 17(5):724-30. PubMed ID: 16437190
    [Abstract] [Full Text] [Related]

  • 15. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
    Tsentidis C, Gourgiotis D, Kossiva L, Doulgeraki A, Marmarinos A, Galli-Tsinopoulou A, Karavanaki K.
    Osteoporos Int; 2016 Apr 12; 27(4):1631-1643. PubMed ID: 26588909
    [Abstract] [Full Text] [Related]

  • 16. Association of OPG-RANKL ratio with left ventricular hypertrophy and geometric remodeling in male overweight/obese youths.
    Zampetti S, Lucantoni F, Pacifico L, Campagna G, Versacci P, Pierimarchi P, Buzzetti R.
    J Endocrinol Invest; 2019 Apr 12; 42(4):427-434. PubMed ID: 30132289
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone mineral density.
    Hamed EA, Mohamed NA, El-Metwally TH, Kamal MM.
    J Pediatr Hematol Oncol; 2010 May 12; 32(4):267-73. PubMed ID: 20445416
    [Abstract] [Full Text] [Related]

  • 19. Bone metabolism, osteoprotegerin, receptor activator of nuclear factor-κB ligand and selected adipose tissue hormones in girls with anorexia nervosa.
    Ostrowska Z, Ziora K, Oświęcimska J, Świętochowska E, Marek B, Kajdaniuk D, Wołkowska-Pokrywa K, Kos-Kudła B.
    Endokrynol Pol; 2014 May 12; 65(1):33-9. PubMed ID: 24549600
    [Abstract] [Full Text] [Related]

  • 20. Changes of serum levels of MMP-3, sRANKL, and OPG in juvenile-onset ankylosing spondylitis patients carrying different HLA-B27 subtypes.
    Mou YK, Zhang PP, Li QX, Lin ZM, Liao ZT, Wei QJ, Gu JR.
    Clin Rheumatol; 2015 Jun 12; 34(6):1085-9. PubMed ID: 25912212
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.